piclidenoson
Small moleculeexperimentalCOVID-19
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started Apr 6, 2020 (NCT04333472)
Timeline
Indications
Mechanism of action
- Adenosine A3 receptorAGONIST
ADORA3 agonist
Chemistry & pharmacology
Loading structure…
SMILES
CNC(=O)[C@H]1O[C@@H](n2cnc3c(NCc4ccc(I)cc4)ncnc32)[C@H](O)[C@@H]1O- Mol. weight
- 510.29 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3989873 ↗
Also known as
- piclidenoson
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06643260 | Phase 3 | Mar 31, 2025 | Can-Fite BioPharma |
| NCT04333472 | Phase 2 | Apr 6, 2020 | Can-Fite BioPharma, Tel Aviv University |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Can-Fite BioPharma | For profit | 2 | 2 | 2 | 2020 |
| Tel Aviv University | Academic/Hospital | 1 | 0 | 1 | 2020 |
2 organizations
Page 1 / 1